Epithalon

Epithalon (Pineal tetrapeptide) is a tetrapeptide (AEDG). The HEIVE catalog describes it as: A Soviet-era pineal extract derivative claimed to influence telomerase; human data is thin and largely single-centre. It is also known as Epitalon, Epithalone and AEDG.

HEIVE groups Epithalon under sleep, cellular maintenance, healthspan and immune balance. These catalog categories are not approved indications or evidence that treatment works. See the product-specific regulatory answer below.

No matching FDA product was identified for Epithalon under the searched names in the October 6, 2026 Drugs@FDA snapshot. This name search does not establish worldwide approval status or exclude differently named products. FDA describes safety concerns or insufficient safety information for the corresponding substance on its compounding-risk page; that listing is not a drug approval.

• FDA product data (October 6, 2026)
• FDA compounding safety information

The HEIVE editorial risk summary for Epithalon lists: Sleep-pattern shifts in the first week. Longer-term concerns: Telomerase activation and cancer risk are theoretically linked. Nobody has studied this in humans. This is not a complete or clinically reviewed safety assessment; risks depend on the product, route and population.

Epithalon has no single onset time established by this catalog. The editorial timeline starts with “Days 1–10”. These are illustrative model or editorial milestones, not clinically validated outcome predictions.

HEIVE's illustrative catalog entry for Epithalon: 5–10 mg daily for 10–20 days per cycle. This is not a verified study range or a prescription. A dose cannot be transferred between products, routes or indications; use the specific approved label and the prescribing clinician's instructions where applicable.

The catalog classifies Epithalon as having limited evidence. Its paper-count snapshot is not a live PubMed search, a count of controlled human trials or proof of safety. This FAQ has not independently validated the catalog's clinical literature claims.

The source catalog lists a nasal form for Epithalon. A listed form is not evidence of an approved or effective treatment. Nasal forms are listed in the source catalog; this does not establish approval, efficacy or equivalent absorption. HEIVE injection calculations do not apply to nasal forms.

Preparation of Epithalon depends on the exact labeled product. Follow its instructions for formulation, diluent, route and storage. A generic powder recipe must not be applied to a prefilled, ready-to-use or differently formulated product. The catalog's mixing example does not establish sterility or stability.

Storage for Epithalon depends on the specific formulation (injectable and nasal in the source catalog). Follow the product's labeled temperature, light protection and expiry or discard instructions. A general refrigerator or 28-day rule does not establish stability or sterility for every preparation.

The HEIVE editorial summary for Epithalon: Run in 10–20 day cycles, twice a year, by convention rather than evidence. This summary is not a clinically validated prediction of tolerance or withdrawal for an individual.

Epithalon and NAD+ share the catalog categories cellular maintenance, sleep and healthspan. Epithalon: A Soviet-era pineal extract derivative claimed to influence telomerase; human data is thin and largely single-centre. NAD+: A coenzyme every cell needs to make energy. Levels fall with age, and the entire longevity case rests on putting them back. This is a catalog comparison, not a head-to-head clinical result or a recommendation to substitute treatments.

• View NAD+

The HEIVE editorial summary highlights: A subset of the cohort work reported melatonin normalisation before any telomere claim. The cited study, population and formulation must be checked before treating this summary as a clinical finding; this FAQ does not supply a verified research citation for it.